Comparability of the characteristics and outcomes of patients with type 2 diabetes recruited to the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and patients in the Fremantle Diabetes Study Phase

    Project Details

    StatusFinished
    Effective start/end date30/11/1631/07/17

    Funding

    • Novo Nordisk Pharmaceuticals Pty Ltd: AUD5,869.00
    • Novo Nordisk Pharmaceuticals Pty Ltd: AUD38,882.00